Cancer Genetics, Agilent Sign FISH Probe Supply Deal

Sep 26, 2018

|

NEW YORK (GenomeWeb) — Cancer Genetics said this week that it has signed a non-exclusive supply agreement with Agilent Technologies for probe reagents for its FISH-based HPV-Associated Cancer Test (FHACT).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Cancer Genetics, Agilent Sign FISH Probe Supply Deal

To read the full story....

Breaking News

William Blair Initiates Coverage of Aspira Women's Health, DermTech With Outperform Ratings

Prenetics Acquires Coronavirus Test Developer Oxsed

Credo Diagnostics Combo Influenza, COVID-19 Test Receives CE-IVD Mark

PerkinElmer SARS-CoV-2 Test Gets Reissued Emergency Use Authorization for Pooled Sampling

Opko Health Q3 Revenues Up 87 Percent

In Brief This Week: LabCorp, Intermountain Health, Progenity, and More

Featured White Papers

IVDR in Light of the COVID Pandemic: The Near Future of In Vitro Diagnostic Testing

What's Popular?

Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test With MilliporeSigma, Hamilton Company

GenMark Diagnostics Expanding Manufacturing to Meet Pent Up Demand for SARS-CoV-2, Respiratory Panel

PerkinElmer SARS-CoV-2 Test Gets Reissued Emergency Use Authorization for Pooled Sampling

Prenetics Acquires Coronavirus Test Developer Oxsed

Inflammatix Awarded $7.4M in Additional BARDA Funding for POC System, Acute Infection Test

Sponsorships